Precision BioSciences, Inc. (DTIL) AI Stock Analysis

Precision BioSciences, Inc., headquartered in Durham, North Carolina, is a clinical stage gene editing company specializing in in vivo gene editing and ex vivo allogeneic CAR T therapies. Its core innovation is the ARCUS genome editing platform, which is designed to modify DNA to treat genetic disorders. The company's ex vivo Allogeneic CAR T Immunotherapy programs genetically engineer T cells outside the body to destroy cancer cells upon reinfusion. Clinical candidates include PBCAR0191 for non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia, as well as PBCAR19B and PBCAR269A for hematological malignancies. The company collaborates with Les Laboratoires Servier, Tiziana Life Sciences, and iECURE, Inc.

Annual revenue has fluctuated significantly, moving from $115.5M in FY2021 down to $25.1M in FY2022, before reaching $68.7M in FY2024 and declining 50.1% to $34.3M in FY2025. Over the 5-year period from FY2020 to FY2025, revenue grew at a CAGR of 7.1%. Aside from FY2024 net income of $7.2M, the company has operated at annual net losses, including a net income of -$45.7M in FY2025. Operating margins were -152.2% in FY2025 and -80.8% over the trailing twelve months, which generated $45.1M in revenue. For the latest quarter ended June 30, 2026, quarterly revenue grew 37272.4% year-over-year.

As of June 30, 2026, Precision BioSciences held $87.5M in cash and short-term investments and $28.1M in total debt, leaving a net cash position of $59.4M. Shareholders' equity was $45.3M against total assets of $125.9M, with a current ratio of 12.82 and a debt-to-equity ratio of 0.62. In FY2025, operating cash flow was -$65.8M and free cash flow was -$65.9M, with capital expenditures of $85,000. Over the past five years, the company's share count increased 1173.7%.

At a share price of $5.77 and a market capitalization of $159.3M, Precision BioSciences carries an enterprise value of $116.1M. The stock trades at a forward P/E of 11.8x, compared to the median of 17.3x for its US-listed Healthcare peers. Its price-to-sales ratio is 3.5x versus the peer median of 4.1x. Over the past year, the stock returned -13.1%, lagging the 16.8% return of the S&P 500 (SPY). Over a 5-year period, the stock declined 98.0%, while the S&P 500 rose 83.0%.

Wall Street sentiment shows 5 Strong Buy ratings, with zero Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $29.40, which is 409.5% above the last close of $5.77. For the fiscal year ending December 31, 2026, analysts estimate revenue of $13.5M and EPS of -$3.87. For the following fiscal year, 2 analysts project revenue of $8.9M, representing a 34.2% decline, alongside EPS of -$1.86. The company beat EPS estimates in each of the last 4 quarters, and the next earnings date is November 2, 2026.

This page is an AI-written research summary of Precision BioSciences, Inc. (DTIL). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: DTIL income statement, DTIL balance sheet, DTIL key metrics, DTIL analyst forecast, DTIL chart. See the DTIL stock overview for the latest quote and news.